A new report estimates that more than four million people in the Americas, Europe, Australia, and New Zealand have consumed ayahuasca at some point in their...
A study has provided new insights into how psychedelics promote plasticity in the brain – suggesting that the antidepressant effects and the hallucinatory effects may have...
Timmy Davis of the Conservative Drug Policy Reform Group (CDPRG) tells Psychedelic Health about the organisation’s campaign to reschedule psilocybin in a bid to increase psychedelic...
A new analysis led by NYU Grossman School of Medicine and the National Drug Early Warning System (NDEWS) at the University of Florida found a 349%...
Algernon NeuroScience (AGN Neuro) has announced that its Phase 1 DMT trial is complete.
A new Ethics Council was launched at the Inaugural Summit of The World’s Leaders in Psychedelics that will work to guide industry standards and best practices.
New research suggests that ketamine nasal spray may prove a safe and effective treatment for refractory chronic migraine.
A study has been launched that is investigating COMP360 psilocybin therapy – an investigational new therapy – for treatment-resistant depression (TRD).
New data released by Sunstone Therapies shows positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD).
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
